Literature DB >> 28045603

Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study.

Erqi L Pollom1, Kyueun Lee1, Ben Y Durkee1, Madeline Grade1, Daniel A Mokhtari1, Daniel R Wahl1, Mary Feng1, Nishita Kothary1, Albert C Koong1, Douglas K Owens1, Jeremy Goldhaber-Fiebert1, Daniel T Chang1.   

Abstract

Purpose To assess the cost-effectiveness of stereotactic body radiation therapy (SBRT) versus radiofrequency ablation (RFA) for patients with inoperable localized hepatocellular carcinoma (HCC) who are eligible for both SBRT and RFA. Materials and Methods A decision-analytic Markov model was developed for patients with inoperable, localized HCC who were eligible for both RFA and SBRT to evaluate the cost-effectiveness of the following treatment strategies: (a) SBRT as initial treatment followed by SBRT for local progression (SBRT-SBRT), (b) RFA followed by RFA for local progression (RFA-RFA), (c) SBRT followed by RFA for local progression (SBRT-RFA), and (d) RFA followed by SBRT for local progression (RFA-SBRT). Probabilities of disease progression, treatment characteristics, and mortality were derived from published studies. Outcomes included health benefits expressed as discounted quality-adjusted life years (QALYs), costs in U.S. dollars, and cost-effectiveness expressed as an incremental cost-effectiveness ratio. Deterministic and probabilistic sensitivity analysis was performed to assess the robustness of the findings. Results In the base case, SBRT-SBRT yielded the most QALYs (1.565) and cost $197 557. RFA-SBRT yielded 1.558 QALYs and cost $193 288. SBRT-SBRT was not cost-effective, at $558 679 per QALY gained relative to RFA-SBRT. RFA-SBRT was the preferred strategy, because RFA-RFA and SBRT-RFA were less effective and more costly. In all evaluated scenarios, SBRT was preferred as salvage therapy for local progression after RFA. Probabilistic sensitivity analysis showed that at a willingness-to-pay threshold of $100 000 per QALY gained, RFA-SBRT was preferred in 65.8% of simulations. Conclusion SBRT for initial treatment of localized, inoperable HCC is not cost-effective. However, SBRT is the preferred salvage therapy for local progression after RFA. © RSNA, 2017 Online supplemental material is available for this article.

Entities:  

Mesh:

Year:  2017        PMID: 28045603      PMCID: PMC5410949          DOI: 10.1148/radiol.2016161509

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  28 in total

1.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

2.  Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria.

Authors:  Kheng Choon Lim; Vivian W Wang; Fahad J Siddiqui; Luming Shi; Edwin S Y Chan; Hong Choon Oh; Say Beng Tan; Pierce K H Chow
Journal:  Hepatology       Date:  2014-05-29       Impact factor: 17.425

3.  Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.

Authors:  Daniel R Wahl; Matthew H Stenmark; Yebin Tao; Erqi L Pollom; Elaine M Caoili; Theodore S Lawrence; Matthew J Schipper; Mary Feng
Journal:  J Clin Oncol       Date:  2015-11-30       Impact factor: 44.544

4.  Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

Authors:  Ben Y Durkee; Yushen Qian; Erqi L Pollom; Martin T King; Sara A Dudley; Jenny L Shaffer; Daniel T Chang; Iris C Gibbs; Jeremy D Goldhaber-Fiebert; Kathleen C Horst
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

Review 5.  Complications of radiofrequency coagulation of liver tumours.

Authors:  S Mulier; P Mulier; Y Ni; Y Miao; B Dupas; G Marchal; I De Wever; L Michel
Journal:  Br J Surg       Date:  2002-10       Impact factor: 6.939

Review 6.  Surgical resection of high-risk hepatocellular carcinoma: patient selection, preoperative considerations, and operative technique.

Authors:  Mark J Truty; Jean-Nicolas Vauthey
Journal:  Ann Surg Oncol       Date:  2010-04-20       Impact factor: 5.344

7.  Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients.

Authors:  G Oster; D M Huse; M J Lacey; A M Epstein
Journal:  Stroke       Date:  1994-06       Impact factor: 7.914

Review 8.  Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities.

Authors:  Jonathan Klein; Laura A Dawson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-12-06       Impact factor: 7.038

9.  Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study.

Authors:  Tito Livraghi; Luigi Solbiati; M Franca Meloni; G Scott Gazelle; Elkan F Halpern; S Nahum Goldberg
Journal:  Radiology       Date:  2003-02       Impact factor: 11.105

10.  Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial.

Authors:  Zhen-Wei Peng; Yao-Jun Zhang; Min-Shan Chen; Li Xu; Hui-Hong Liang; Xiao-Jun Lin; Rong-Ping Guo; Ya-Qi Zhang; Wan Yee Lau
Journal:  J Clin Oncol       Date:  2012-12-26       Impact factor: 44.544

View more
  12 in total

Review 1.  Stereotactic body radiation therapy in primary hepatocellular carcinoma: current status and future directions.

Authors:  Timothy A Lin; Jessica S Lin; Timothy Wagner; Ngoc Pham
Journal:  J Gastrointest Oncol       Date:  2018-10

Review 2.  [Image-guided, minimally invasive surgery and other local therapeutic procedures for primary liver tumors].

Authors:  D L Stippel; R Wahba; C J Bruns; A Bunck; C Baues; T Persigehl
Journal:  Chirurg       Date:  2018-11       Impact factor: 0.955

3.  Improving Adjuvant Liver-Directed Treatment Recommendations for Unresectable Hepatocellular Carcinoma: An Artificial Intelligence-Based Decision-Making Tool.

Authors:  Allen Mo; Christian Velten; Julie M Jiang; Justin Tang; Nitin Ohri; Shalom Kalnicki; Parsa Mirhaji; Kei Nemoto; Boudewijn Aasman; Madhur Garg; Chandan Guha; N Patrik Brodin; Rafi Kabarriti
Journal:  JCO Clin Cancer Inform       Date:  2022-06

Review 4.  Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review.

Authors:  Abdalla Aly; Sarah Ronnebaum; Dipen Patel; Yunes Doleh; Fernando Benavente
Journal:  Hepat Oncol       Date:  2020-07-21

5.  Cost-Effectiveness Analysis of Selective Internal Radiotherapy With Yttrium-90 Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma.

Authors:  Kathryn E Marqueen; Edward Kim; Celina Ang; Madhu Mazumdar; Michael Buckstein; Bart S Ferket
Journal:  JCO Oncol Pract       Date:  2021-01-08

6.  Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis.

Authors:  Shuling Chen; Zhenwei Peng; Mengchao Wei; Weifeng Liu; Zihao Dai; Haibo Wang; Jie Mei; Mingfong Cheong; Hanmei Zhang; Ming Kuang
Journal:  BMC Cancer       Date:  2018-04-05       Impact factor: 4.430

Review 7.  Health economic evaluation of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma: a systematic review.

Authors:  Haiyin Wang; Chunlin Jin; Liang Fang; Hui Sun; Wendi Cheng; Shanlian Hu
Journal:  Cost Eff Resour Alloc       Date:  2020-01-10

8.  Radiofrequency ablation vs. stereotactic body radiotherapy for stage IA non-small cell lung cancer in nonsurgical patients.

Authors:  Ming Li; Xiao Xu; Yingyi Qin; Peng Zhang; Changxing Shen; Qing Xia; Lihong Fan
Journal:  J Cancer       Date:  2021-03-19       Impact factor: 4.207

9.  Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4-B1: a pilot study.

Authors:  Feiqian Wang; Kazushi Numata; Atsuya Takeda; Katsuaki Ogushi; Hiroyuki Fukuda; Hiromi Nihonmatsu; Koji Hara; Makoto Chuma; Yuichirou Tsurugai; Shin Maeda
Journal:  BMC Cancer       Date:  2021-10-30       Impact factor: 4.430

10.  Selection of external beam radiotherapy approaches for precise and accurate cancer treatment.

Authors:  Hiroki Shirato; Quynh-Thu Le; Keiji Kobashi; Anussara Prayongrat; Seishin Takao; Shinichi Shimizu; Amato Giaccia; Lei Xing; Kikuo Umegaki
Journal:  J Radiat Res       Date:  2018-03-01       Impact factor: 2.724

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.